Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Gross Profit: 2015-2025

Historic Gross Profit for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to $7.5 million.

  • Editas Medicine's Gross Profit rose 12265.57% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.4 million, marking a year-over-year decrease of 24.90%. This contributed to the annual value of $32.3 million for FY2024, which is 58.64% down from last year.
  • As of Q3 2025, Editas Medicine's Gross Profit stood at $7.5 million, which was up 110.82% from $3.6 million recorded in Q2 2025.
  • Over the past 5 years, Editas Medicine's Gross Profit peaked at $60.0 million during Q4 2023, and registered a low of $42,000 during Q3 2022.
  • Over the past 3 years, Editas Medicine's median Gross Profit value was $4.7 million (recorded in 2025), while the average stood at $11.5 million.
  • Its Gross Profit has fluctuated over the past 5 years, first plummeted by 99.32% in 2022, then surged by 12,604.76% in 2023.
  • Over the past 5 years, Editas Medicine's Gross Profit (Quarterly) stood at $12.5 million in 2021, then plummeted by 47.58% to $6.5 million in 2022, then spiked by 818.74% to $60.0 million in 2023, then tumbled by 49.03% to $30.6 million in 2024, then skyrocketed by 12,265.57% to $7.5 million in 2025.
  • Its last three reported values are $7.5 million in Q3 2025, $3.6 million for Q2 2025, and $4.7 million during Q1 2025.